TA
Tim Anderson BofA Securities Latest Price Targets & Analyst Ratings
Main Sector
Healthcare
Ratings Past Year
38
Avg Return
Past Year
Past Year
12%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past Year
Buy
31.6%
Hold
44.7%
Sell
23.7%
| Stock | Rating | Price Target |
Upside Downside |
Ratings 1 Year |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
|---|---|---|---|---|---|---|---|---|
Johnson & Johnson
JNJ
$459B
|
Hold
Maintained
| $198 |
4%
upside
| 7 | – |
–
| 3 Oct ‘25 9 days ago |
|
Pfizer
PFE
$141B
|
Hold
Maintained
| $30 |
21%
upside
| 3 | – |
–
| 3 Oct ‘25 9 days ago |
|
Amgen
AMGN
$156B
|
Sell
Maintained
| $272 |
6%
downside
| 6 | -1.2% |
0
%
| 26 Sep ‘25 16 days ago |
|
Apogee Therapeutics
APGE
$3.13B
|
Buy
Maintained
| $87 |
66%
upside
| 1 | +39% |
0
%
| 28 Aug ‘25 1 month ago |
|
|
MTSR
Metsera Inc
MTSR
$5.57B
|
Buy
Maintained
| $50 |
5%
downside
| 2 | +34% |
0
%
| 28 Aug ‘25 1 month ago |
|
|
AARD
Aardvark Therapeutics
AARD
$353M
|
Buy
Maintained
| $25 |
54%
upside
| 3 | +23% |
0
%
| 28 Aug ‘25 1 month ago |
|
AbbVie
ABBV
$407B
|
Hold
Maintained
| $204 |
11%
downside
| 4 | – |
–
| 28 Apr ‘25 5 months ago |
|
Regeneron Pharmaceuticals
REGN
$59.8B
|
Sell
Maintained
| $547 |
3%
downside
| 2 | +14% |
0
%
| 17 Apr ‘25 5 months ago |
|
Gilead Sciences
GILD
$145B
|
Buy
Maintained
| $126 |
8%
upside
| 3 | +9.1% |
0
%
| 5 Mar ‘25 7 months ago |
|
Moderna
MRNA
$10.4B
|
Sell
Maintained
| $34 |
27%
upside
| 2 | +23% |
0
%
| 11 Feb ‘25 8 months ago |
|
Merck
MRK
$215B
|
Buy
Maintained
| $112 |
30%
upside
| 2 | -8.9% |
0
%
| 5 Feb ‘25 8 months ago |
|
Bristol-Myers Squibb
BMY
$89.5B
|
Hold
Reinstated
| $63 |
43%
upside
| 1 | – |
–
| 10 Dec ‘24 10 months ago |
|
Biogen
BIIB
$21.5B
|
Hold
Reinstated
| $178 |
21%
upside
| 1 | – |
–
| 10 Dec ‘24 10 months ago |
|
Eli Lilly
LLY
$747B
|
Buy
Reinstated
| $997 |
20%
upside
| 1 | +3.7% |
0
%
| 10 Dec ‘24 10 months ago |
|